Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Non-Current Deffered Revenue (2016 - 2025)

Historic Non-Current Deffered Revenue for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Q3 2025 value amounting to $12.5 million.

  • Lineage Cell Therapeutics' Non-Current Deffered Revenue fell 2235.51% to $12.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.5 million, marking a year-over-year decrease of 2235.51%. This contributed to the annual value of $14.4 million for FY2024, which is 2278.93% down from last year.
  • As of Q3 2025, Lineage Cell Therapeutics' Non-Current Deffered Revenue stood at $12.5 million, which was down 2235.51% from $12.8 million recorded in Q2 2025.
  • Lineage Cell Therapeutics' Non-Current Deffered Revenue's 5-year high stood at $32.5 million during Q4 2021, with a 5-year trough of $12.5 million in Q3 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' median Non-Current Deffered Revenue value was $19.9 million (recorded in 2023), while the average stood at $20.9 million.
  • Per our database at Business Quant, Lineage Cell Therapeutics' Non-Current Deffered Revenue crashed by 3257.71% in 2023 and then crashed by 1450.11% in 2024.
  • Quarter analysis of 5 years shows Lineage Cell Therapeutics' Non-Current Deffered Revenue stood at $32.5 million in 2021, then dropped by 14.57% to $27.7 million in 2022, then crashed by 32.58% to $18.7 million in 2023, then fell by 22.79% to $14.4 million in 2024, then dropped by 13.66% to $12.5 million in 2025.
  • Its last three reported values are $12.5 million in Q3 2025, $12.8 million for Q2 2025, and $13.6 million during Q1 2025.